Nourianz

Chemical Nameistradefylline
Dosage FormTablet (oral; 20 mg, 40 mg)
Drug ClassReceptor antagonists
SystemMusculoskeletal
CompanyKyowa Kirin Inc.
Approval Year2019

Indication

  • Nourianz is indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) experiencing “off” episodes.
Last updated on 11/10/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Nourianz (istradefylline) Prescribing Information2019Kyowa Kirin